These defects induced by HER-2/neu in components of the antigen processing and presentation machinery hinder the in vivo generation of Class I restricted HER-2 derived epitopes, lowering tumor peptide recognition by CD8+ T cells [41]. This evidence concerns the gene ERBB2 and neoplasm.